Transcode Therapeutics Inc Stock Price, News & Analysis

TransCode Therapeutics (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative announced a collaboration to evaluate TTX-MC138 in the Quantum Leap PRE-I-SPY Phase 2a dose-expansion trial for colorectal cancer.

The Phase 2a will enroll up to 45 patients with ctDNA-positive minimal residual disease who completed curative-intent therapy, is planned to begin in H1 2026, and will be led by Dr. Paula Pohlmann at MD Anderson. The move follows TransCode's Phase 1a observation of an encouraging safety profile and durable anti-tumor effects, which the companies say support further efficacy testing in the MRD setting where recurrence risk is high.

TransCode Therapeutics (NASDAQ: RNAZ) on November 17, 2025 appointed Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer, initially part-time. Dr. Janicot brings >35 years in pharmaceutical research and early clinical development with expertise in RNA biology, translational medicine, and oncology strategy. He will support strategic R&D and clinical development for lead programs TTX-MC138 and Seviprotimut-L as they advance toward late-stage trials.

Dr. Janicot founded JMi ONConsulting, has led programs at Janssen, and authored >360 scientific works.

TransCode Therapeutics (NASDAQ: RNAZ) reported completion of its Phase 1a trial of TTX-MC138, an investigational miR-10b inhibitor, and met the trial's primary safety endpoint. Sixteen patients were treated across four dose levels with no dose-limiting toxicities observed and a recommended Phase 2 dose established. Median treatment duration was 4 months (range 2–12 months); three patients remain on study. Forty-four percent (7/16) had stable disease ≥4 months. Positive pharmacodynamic effects were seen across the dose range. Data are preliminary; a poster presentation is scheduled for ESMO, Oct 17–21, 2025, and a Phase 2a trial is planned.

TransCode Therapeutics (NASDAQ: RNAZ) announced on October 8, 2025 the acquisition of 100% of Polynoma and a concurrent $25 million equity investment from CK Life Sciences. The deal adds Polynoma’s Phase 3–ready seviprotimut-L (a polyvalent shed‑antigen vaccine for adjuvant treatment of stage IIB/IIC melanoma) to TransCode’s microRNA pipeline.

Proceeds will primarily advance TransCode’s lead microRNA asset, TTX‑MC138, into a Phase 2 trial. Philippe Calais becomes CEO and remains board chair; Tom Fitzgerald returns to CFO; Elizabeth Czerepak joins as independent board member and audit chair. The company expects to retain Polynoma development, finance, and manufacturing staff.

TransCode Therapeutics (RNAZ) has appointed Dr. Phillip D. Zamore to its Scientific Advisory Board. Dr. Zamore is a distinguished RNA pioneer who co-founded Alnylam Pharmaceuticals in 2002, which developed the first FDA-approved RNAi drug. Currently serving as the Gretchen Stone Cook Professor of Biomedical Sciences at UMass Chan Medical School, Dr. Zamore chairs the RNA Therapeutics Institute. His groundbreaking research in RNA interference and microRNA processing has earned him membership in prestigious institutions including the National Academy of Sciences. Dr. Zamore will contribute his expertise to advance TransCode's pipeline of RNA-targeted cancer therapies.

TransCode Therapeutics (NASDAQ: RNAZ) has announced successful completion of initial dosing in Cohort 4 of its Phase 1a clinical trial for TTX-MC138. Key highlights include:

- 15 patients treated across 4 dose levels (0.8 mg/kg to 4.8 mg/kg)
- No significant safety or dose-limiting toxicities reported
- 10 patients remain on study with stable disease
- Two patients received 7 doses over ~7 months showing stable disease
- PK/PD data shows predictable dose-response relationship
- Evidence of miR-10b target engagement at 24 hours post-infusion in Cohorts 1 and 2
- Safety Review Committee approved expanded enrollment in Cohort 3

The positive results support advancement to the Phase 1b dose expansion portion of the trial.

TransCode Therapeutics (NASDAQ: RNAZ) has announced a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EST. The split aims to increase the per-share trading price to meet Nasdaq's minimum bid price requirement for continued listing. The reverse split will reduce outstanding common shares from 23,341,336 to approximately 833,620. The company's stock will continue trading under the symbol "RNAZ" on the Nasdaq Capital Market.

Stockholders will receive one new share for every 28 current shares, with fractional shares rounded up to the nearest whole number. Proportional adjustments will be made to outstanding stock options, warrants, and shares under stock incentive plans. Vstock Transfer LLC will serve as the exchange agent, and the company's CUSIP number will change to 89357L 501.

TransCode Therapeutics (NASDAQ: RNAZ) has announced a 1-for-28 reverse stock split approved by its Board of Directors and stockholders on May 2, 2025. The split aims to increase the company's per share trading price to meet Nasdaq's minimum bid price requirements for continued listing. The reverse split will reduce outstanding common shares from 23,341,336 to approximately 833,620.

The conversion will automatically convert 28 current shares into one new share, with fractional shares rounded up to the nearest whole number. Proportional adjustments will be made to outstanding stock options, warrants, and shares under stock incentive plans. Vstock Transfer LLC will serve as the exchange agent, with the effective date to be announced at least two business days prior to implementation.

TransCode Therapeutics (NASDAQ: RNAZ) reported positive progress in its Phase 1a clinical trial of TTX-MC138, a first-in-class therapeutic targeting miR-10b for metastatic cancer treatment. Key findings include:

- 13 patients received treatment across 4 dose levels (0.8 mg/kg to 4.8 mg/kg)
- No significant safety or dose-limiting toxicities reported
- Two patients maintained stable disease for ~7 months
- 8 patients continue treatment in 28-day cycles
- PK/PD analysis shows promising results with miR-10b target engagement in 5 out of 6 analyzed patients

The positive tolerability profile and PK/PD results support advancement to the Phase 1b expansion portion of the trial.